BR112014020821A2 - molécula de ligação a antígeno para promoção de desaparecimento de antígeno através de fcyriib - Google Patents
molécula de ligação a antígeno para promoção de desaparecimento de antígeno através de fcyriibInfo
- Publication number
- BR112014020821A2 BR112014020821A2 BR112014020821A BR112014020821A BR112014020821A2 BR 112014020821 A2 BR112014020821 A2 BR 112014020821A2 BR 112014020821 A BR112014020821 A BR 112014020821A BR 112014020821 A BR112014020821 A BR 112014020821A BR 112014020821 A2 BR112014020821 A2 BR 112014020821A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- binding
- molecule
- binding activity
- fcrn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
abstract the present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an fc?-binding domain having fc? riib-selective binding activity, and (iii) an fcrn-binding domain having fcrn-binding activity under an acidic ph range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule. tradução do resumo resumo patente de invenção: "molécula de ligação a antígeno para promoção de desaparecimento de antígeno através de fc?riib". a presente invenção refere-se a moléculas de ligação a antígeno contendo (i) um domínio de ligação a antígeno cuja atividade de ligação a antígeno varia dependendo das condições de concentração de íons, (ii) um domínio de ligação a fc? tendo atividade de ligação seletiva ao fc?riib e (iii) um domínio de ligação a fcrn tendo atividade de ligação ao fcrn sob uma condição de faixa de ph ácido e métodos de diminuição da concentração plasmática de antígeno quando comparado com antes da administração da molécula, os quais incluem a etapa de administração da molécula.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2012/054624 WO2012115241A1 (ja) | 2011-02-25 | 2012-02-24 | FcγRIIb特異的Fc抗体 |
JPPCT/JP2012/054624 | 2012-02-24 | ||
JP2012-185866 | 2012-08-24 | ||
JP2012185866 | 2012-08-24 | ||
PCT/JP2012/075092 WO2013047752A1 (ja) | 2011-09-30 | 2012-09-28 | 抗原の消失を促進する抗原結合分子 |
JPPCT/JP2012/075092 | 2012-09-28 | ||
PCT/JP2013/054461 WO2013125667A1 (ja) | 2012-02-24 | 2013-02-22 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014020821A2 true BR112014020821A2 (pt) | 2017-07-04 |
BR112014020821B1 BR112014020821B1 (pt) | 2022-11-16 |
Family
ID=49005844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014020821-2A BR112014020821B1 (pt) | 2012-02-24 | 2013-02-22 | Composição farmacêutica e método de produção de uma molécula de ligação a antígeno |
Country Status (16)
Country | Link |
---|---|
US (2) | US20160046693A1 (pt) |
EP (2) | EP3738980A1 (pt) |
JP (5) | JP6138108B2 (pt) |
KR (3) | KR102219987B1 (pt) |
CN (2) | CN107266564A (pt) |
AU (3) | AU2013223087B2 (pt) |
BR (1) | BR112014020821B1 (pt) |
CA (1) | CA2865158C (pt) |
DK (1) | DK2818183T3 (pt) |
ES (1) | ES2795419T3 (pt) |
HK (1) | HK1201476A1 (pt) |
MX (2) | MX370668B (pt) |
RU (1) | RU2736349C2 (pt) |
SG (2) | SG11201405137QA (pt) |
TW (4) | TWI682939B (pt) |
WO (1) | WO2013125667A1 (pt) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
CN102056946A (zh) | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CN103052649B (zh) | 2010-07-29 | 2015-12-16 | Xencor公司 | 具有修改的等电点的抗体 |
KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
DK2857420T3 (da) | 2012-05-30 | 2020-11-23 | Chugai Pharmaceutical Co Ltd | Målvævsspecifikt antigenbindende molekyle |
DK2857419T3 (da) * | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
JP6774164B2 (ja) * | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
TW202340236A (zh) | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
JP6618362B2 (ja) | 2013-01-14 | 2019-12-11 | ゼンコア インコーポレイテッド | 新規異種二量体タンパク質 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
EP3078744B1 (en) | 2013-12-04 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
EP3194449A1 (en) | 2014-07-24 | 2017-07-26 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
WO2016086196A2 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
PT3233921T (pt) | 2014-12-19 | 2021-12-09 | Chugai Pharmaceutical Co Ltd | Anticorpos anti-c5 e processos para a sua utilização |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
AR105634A1 (es) | 2015-09-18 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que se unen a il 8 y sus usos |
JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Cd3及びpsmaに結合するヘテロ二量体抗体 |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
EP3470424A4 (en) * | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY |
KR20230054508A (ko) | 2016-06-14 | 2023-04-24 | 젠코어 인코포레이티드 | 이중특이적 체크포인트 억제제 항체 |
TWI611811B (zh) | 2016-06-17 | 2018-01-21 | 中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
MX2018016265A (es) | 2016-06-28 | 2019-07-04 | Xencor Inc | Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina. |
CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018071918A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
MA50958A (fr) | 2017-04-21 | 2020-10-14 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs méthodes d'utilisation |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
KR101987272B1 (ko) * | 2017-09-15 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A28.1 |
KR101986252B1 (ko) * | 2017-09-15 | 2019-06-05 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A28 |
CN107621548A (zh) * | 2017-09-15 | 2018-01-23 | 深圳市因诺赛生物科技有限公司 | 人全血中游离型及细胞结合型总IgE测定诊断试剂盒及制备方法 |
KR101987292B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2B45.1 |
KR101987279B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A45.1 |
KR101987268B1 (ko) * | 2017-10-12 | 2019-06-10 | 국민대학교 산학협력단 | Fc 감마 수용체 변이체 MG2A45 |
WO2019087115A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質 |
CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
EA202190451A1 (ru) | 2018-08-10 | 2021-07-13 | Чугаи Сейяку Кабусики Кайся | Анти-cd137 антигенсвязывающие молекулы и их применение |
EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
SG11202109406TA (en) | 2019-03-01 | 2021-09-29 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3 |
CN113613676A (zh) | 2019-03-19 | 2021-11-05 | 中外制药株式会社 | 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库 |
EP4076663A1 (en) | 2019-12-18 | 2022-10-26 | F. Hoffmann-La Roche AG | Bispecific anti-ccl2 antibodies |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-CTLA-4 antibodies |
CR20240026A (es) | 2021-06-25 | 2024-03-14 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-ctla-4 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
EP1780273B1 (en) | 2001-06-22 | 2010-10-06 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
US20050260213A1 (en) * | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
PT1562972E (pt) | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
KR100863776B1 (ko) * | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 |
ES2426816T3 (es) * | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
RU2367667C2 (ru) | 2004-08-19 | 2009-09-20 | Дженентек, Инк. | Полипептидные варианты с измененной эффекторной функцией |
EP1812068A4 (en) | 2004-10-29 | 2010-06-09 | Medimmune Inc | METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1829961A4 (en) | 2004-12-22 | 2008-06-04 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
JP2009545322A (ja) | 2006-08-02 | 2009-12-24 | ザ ユーエービー リサーチ ファウンデーション | 規定された抗原特異性の可溶性モノクロナール可変性リンパ球受容体に関連する方法および組成物 |
PL2059536T3 (pl) | 2006-08-14 | 2014-07-31 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
CN103408661B (zh) | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
WO2008150494A1 (en) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
CA2958185C (en) | 2007-12-26 | 2020-08-25 | Xencor, Inc. | Fc variants with altered binding to fcrn |
EP2238156B1 (en) * | 2008-01-29 | 2014-10-01 | Ablynx N.V. | Methods to stabilize proteins and polypeptides |
CN102056946A (zh) * | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
CN104479017A (zh) * | 2008-04-25 | 2015-04-01 | 戴埃克斯有限公司 | 针对fcrn的抗体及其用途 |
US20100098730A1 (en) | 2008-10-14 | 2010-04-22 | Lowman Henry B | Immunoglobulin variants and uses thereof |
SG10201704214VA (en) | 2009-01-29 | 2017-06-29 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
EP3674317A1 (en) * | 2009-03-19 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
SG10201609665PA (en) * | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
EP3825325A3 (en) * | 2011-03-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
BR112014007687B1 (pt) * | 2011-09-30 | 2022-12-06 | Chugai Seiyaku Kabushiki Kaisha | Composiçâo farmacêutica de anticorpos para eliminação de antígenos no plasma |
CA2850322C (en) * | 2011-09-30 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
US20150050269A1 (en) * | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW202340236A (zh) * | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
WO2014133515A1 (en) * | 2013-02-28 | 2014-09-04 | Hewlett-Packard Development Company, L.P. | Arranging elements in a layout |
-
2013
- 2013-02-22 SG SG11201405137QA patent/SG11201405137QA/en unknown
- 2013-02-22 ES ES13751098T patent/ES2795419T3/es active Active
- 2013-02-22 MX MX2014010140A patent/MX370668B/es active IP Right Grant
- 2013-02-22 TW TW107102927A patent/TWI682939B/zh active
- 2013-02-22 BR BR112014020821-2A patent/BR112014020821B1/pt active IP Right Grant
- 2013-02-22 AU AU2013223087A patent/AU2013223087B2/en active Active
- 2013-02-22 RU RU2014138499A patent/RU2736349C2/ru active
- 2013-02-22 CA CA2865158A patent/CA2865158C/en active Active
- 2013-02-22 EP EP20167071.8A patent/EP3738980A1/en active Pending
- 2013-02-22 US US14/379,825 patent/US20160046693A1/en not_active Abandoned
- 2013-02-22 TW TW111101638A patent/TW202231872A/zh unknown
- 2013-02-22 TW TW108146154A patent/TW202015731A/zh unknown
- 2013-02-22 TW TW102106149A patent/TWI617577B/zh active
- 2013-02-22 CN CN201710422847.2A patent/CN107266564A/zh active Pending
- 2013-02-22 KR KR1020147026038A patent/KR102219987B1/ko active IP Right Grant
- 2013-02-22 JP JP2014500939A patent/JP6138108B2/ja active Active
- 2013-02-22 KR KR1020217004640A patent/KR102475951B1/ko active IP Right Grant
- 2013-02-22 DK DK13751098.8T patent/DK2818183T3/da active
- 2013-02-22 SG SG10201805584YA patent/SG10201805584YA/en unknown
- 2013-02-22 KR KR1020227032337A patent/KR20220136441A/ko not_active Application Discontinuation
- 2013-02-22 WO PCT/JP2013/054461 patent/WO2013125667A1/ja active Application Filing
- 2013-02-22 CN CN201380021594.8A patent/CN104244980B/zh active Active
- 2013-02-22 EP EP13751098.8A patent/EP2818183B1/en active Active
-
2014
- 2014-08-22 MX MX2018013128A patent/MX2018013128A/es unknown
-
2015
- 2015-03-03 HK HK15102123.9A patent/HK1201476A1/xx unknown
-
2017
- 2017-04-25 JP JP2017085757A patent/JP6669688B2/ja active Active
-
2018
- 2018-04-16 AU AU2018202643A patent/AU2018202643A1/en not_active Abandoned
- 2018-04-30 AU AU2018202968A patent/AU2018202968B2/en active Active
-
2020
- 2020-01-07 JP JP2020000697A patent/JP7012104B2/ja active Active
-
2022
- 2022-01-17 JP JP2022004759A patent/JP7411698B2/ja active Active
- 2022-06-30 US US17/854,023 patent/US20230140797A1/en active Pending
-
2023
- 2023-12-25 JP JP2023217513A patent/JP2024038068A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014020821A2 (pt) | molécula de ligação a antígeno para promoção de desaparecimento de antígeno através de fcyriib | |
SG10201907215QA (en) | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
MX2016012716A (es) | Compuestos y metodos para suministro trans-membrana de moleculas. | |
BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
EA201490420A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ | |
BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
BR112013021963A2 (pt) | sistema e método de separação de sangue para uma tira de teste seca | |
EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
BR112016014853A8 (pt) | cartucho adsorvente, método para regenerar ou purificar fluido de diálise, sistema de diálise para regenerar ou purificar fluido usado de diálise e método para fabricar um cartucho adsorvente | |
BR112014023898A2 (pt) | moléculas de ácido nucleico artificiais compreendendo 5''utr top | |
EA201691060A1 (ru) | Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии | |
MX364886B (es) | Lente oftálmica con sistema microfluídico. | |
EA201301336A1 (ru) | Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии | |
TR201906285T4 (tr) | İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi. | |
MX353550B (es) | Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. | |
BR112015021681A2 (pt) | proteínas de ligação para pcsk9 | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
BR112016015718A2 (pt) | Processo de purificação de aminoácidos aromáticos | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
EA201890198A1 (ru) | Новые белки, специфичные в отношении lag-3 | |
EA201490901A1 (ru) | Линкеры на основе тирозина для свободного соединения пептидов | |
EA201600288A1 (ru) | Замещенные фенилаланиновые производные |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/02/2013, OBSERVADAS AS CONDICOES LEGAIS |